목적: We aim to share our initial experience of dupilumab for chronic rhinosinusitis with nasal polyp patients who underwent endoscopic sinus surgery and have steroid-dependent olfactory disturbance in Korea. 방법:A retrospective review of 18 patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyp and have steroid- dependent olfactory disturbance prescribed dupilumab from March 2021 to August 2021 at SNU Boramae medical center was performed. Their demographic, clinical, endoscopic, and lab data were evaluated. Olfactory function was checked with the patient’s VAS score and classified into 4 groups by improvement proportion (quartile). 결과:The average medication starting date was postoperative day 4 years. (Standard deviation (SD): 1138 days, range: 55 days to 10 years.) The mean blood eosinophil and total IgE were 929.3/μL (SD: 1252.9) and 352.7KU/L (SD: 311.4), respectively. Patients were planned to get dupilumab injection every 2 weeks in 2 months and as needed after 2months. The average injection rate was 1.64 injections/month (SD: 0.47, range: 0.75-2). Excellent (n=6), good (n=8), and fair/poor (n=4) improvement of olfactory dysfunction were reported, showing mean blood eosinophil count of 1564.3, 801.3, and 232.8; mean total IgE levels of 1320.3, 152.1, and 310.4; asthma comorbidity of 67%, 75%, and 25%; postoperative days of 659, 2062, and 1268, respectively. 결론:77.8% of postoperative steroid dependent olfactory disturbance showed early good response to dupilumab in our study. Type 2 inflammatory markers such as higher blood eosinophil count, higher total IgE, and asthma comorbidity could be indicators for good response to dupilumab.